ICU Medical Q2 Earnings Call: Stable Revenue Amid Tariff Challenges, Adjusted Guidance

ICU Medical reported Q2 revenue of $544 million, a 2% organic growth, and adjusted EBITDA of $100 million. The consumables business saw a 4% organic growth, while the IV Systems business experienced a 2% organic growth. However, the company faces challenges due to increased tariffs impacting profitability, prompting adjusted guidance. Despite these hurdles, ICU Medical remains committed to mitigating these impacts while continuing to invest in innovation and infrastructure improvements.

ICU Medical (NASDAQ:ICUI), a leading provider of medical products for infusion therapy, vascular access, and vital care applications, reported its second quarter (Q2) 2025 financial results. The company's revenue for the quarter was $548.9 million, representing an 8% year-on-year decline but beating analysts' expectations by 1.7%. Adjusted EBITDA was $100.3 million, exceeding estimates by 10.5%.

Key highlights of the Q2 results include:

- Revenue: $548.9 million, a 8% year-on-year decline, but 1.7% above analyst estimates.
- GAAP Profit per Share: $1.43, significantly above analysts' consensus estimates of -$0.47.
- Adjusted EBITDA: $100.3 million, up 18.3% year-on-year and 10.5% above estimates.

The company's Chief Executive Officer, Vivek Jain, noted that the results were generally in line with expectations. However, the revenue decline can be attributed to the company's Vital Care segment, which saw a $63 million decrease in revenue, impacting overall revenue [2].

ICU Medical's full-year guidance was also updated to reflect the impact of increased tariffs on profitability. The adjusted EBITDA guidance for the full year was revised to $380 million to $390 million, and the adjusted EPS guidance was updated to $6.85 to $7.15. The company expects its GAAP net loss to narrow to $(43) million to $(35) million [3].

The company's consumables business saw a 4% organic growth, while the IV Systems business experienced a 2% organic growth. However, these gains were offset by a significant decline in the Vital Care segment, which saw a $63 million decrease in revenue [2].

Despite the challenges posed by increased tariffs, ICU Medical remains committed to mitigating these impacts and continuing to invest in innovation and infrastructure improvements. The company's strong performance in the consumables and IV Systems segments indicates a potential for future growth.

References:
[1] https://finance.yahoo.com/news/icu-medical-nasdaq-icui-q2-083330019.html
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_PLX59368D:0-icu-medical-q2-revenue-adjusted-eps-beats-estimates/
[3] https://finance.yahoo.com/news/icu-medical-announces-second-quarter-200500066.html